HER-2/neu peptide vaccine
Sponsors
University of Washington, Case Comprehensive Cancer Center, Mayo Clinic
Conditions
Breast CancerHER2-positive Breast CancerHER2/Neu PositiveHLA-A2 Positive Cells PresentLung CancerMale Breast CancerOvarian CancerRecurrent Breast Cancer
Early Phase 1
Phase 1
HER-2 Protein Vaccine in Treating Women With Breast Cancer
CompletedNCT00068614
Start: 2003-07-31Updated: 2014-02-05
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
CompletedNCT00005023
Start: 1999-03-31End: 2001-01-31Updated: 2017-11-30
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
CompletedNCT00003002
Start: 1996-04-30End: 2004-01-31Updated: 2019-02-27
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
CompletedNCT00194714
Start: 2016-05-31End: 2023-05-22Updated: 2024-06-06
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
CompletedNCT00791037
Start: 2008-10-31End: 2014-12-31Updated: 2017-05-25
Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
WithdrawnNCT01219907
Start: 2012-06-30Updated: 2013-05-17
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
CompletedNCT01355393
Start: 2011-07-31Updated: 2020-02-10
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
CompletedNCT01632332
Start: 2012-07-09End: 2018-07-09Updated: 2018-10-09